Back to top
more

Mirati Therapeutics, Inc. (MRTX)

(Real Time Quote from BATS)

$132.25 USD

132.25
173,452

+6.44 (5.12%)

Updated Aug 12, 2020 02:54 PM ET

3-Hold of 5     3    

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.33%
2Buy17.77%
3Hold9.37%
4Sell4.88%
5Strong Sell1.79%
S&P50010.56%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

F Value F Growth B Momentum F VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

Analysts Estimate Mirati (MRTX) to Report a Decline in Earnings: What to Look Out for

Mirati (MRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Mirati (MRTX) Up 4.1% Since Last Earnings Report: Can It Continue?

Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Mirati (MRTX) Reports Q1 Loss, Lags Revenue Estimates

Mirati (MRTX) delivered earnings and revenue surprises of -22.42% and -58.92%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Mirati (MRTX) to Report a Decline in Earnings: What to Look Out for

Mirati (MRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kinjel Shah

4 Drug/Biotech Outperformers That May Lose Steam in 2020

Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.

Zacks Equity Research

Options Traders Expect Huge Moves in Mirati (MRTX) Stock

Investors need to pay close attention to Mirati (MRTX) stock based on the movements in the options market lately.

Zacks Equity Research

Mirati (MRTX) Reports Q3 Loss, Tops Revenue Estimates

Mirati (MRTX) delivered earnings and revenue surprises of -8.66% and 97.60%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Are Options Traders Betting on a Big Move in Mirati Therapeutics (MRTX) Stock?

Investors need to pay close attention to Mirati Therapeutics (MRTX) stock based on the movements in the options market lately.

Zacks Equity Research

Amgen's KRAS Inhibitor Shows Response in Larger NSCLC Group

Amgen's (AMGN) novel investigational KRAS inhibitor, AMG 510, for solid tumor shows anti-tumor activity in a larger group of NSCLC patients.

Zacks Equity Research

Mirati Inks Deal with Novartis to Evaluate Tumor Candidate

Mirati (MRTX) inks a clinical collaboration with Novartis to evaluate the combination of the former's MRTX849 and the latter's SHP2 inhibitor, TNO155, in patients with advanced solid tumors.

Zacks Equity Research

Implied Volatility Surging for Mirati Therapeutics (MRTX) Stock Options

Investors need to pay close attention to Mirati Therapeutics (MRTX) stock based on the movements in the options market lately.

Zacks Equity Research

Amgen's KRAS Inhibitor Shows Impressive Anti-Tumor Activity

At ASCO, Amgen (AMGN) presented encouraging initial data set for AMG 510, its novel investigational KRAS inhibitor for solid tumor.

Neena Mishra

Why Cancer-Fighting Stocks & ETFs Are Soaring

The cancer immunotherapy ETF is soaring today as some of its holdings presented very promising results at the ASCO conference. Find out more on the podcast.

Zacks Equity Research

Options Traders Expect Huge Moves in Mirati Therapeutics (MRTX) Stock

Investors need to pay close attention to Mirati Therapeutics (MRTX) stock based on the movements in the options market lately.

Zacks Equity Research

Mirati Therapeutics (MRTX) Catches Eye: Stock Jumps 5.4%

Mirati Therapeutics (MRTX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Neena Mishra

Nobel Prize for Cancer Immunotherapy & Biotech ETFs to Buy

2018 Nobel Prize for medicine was awarded for immunotherapy research. Here is what investors need to know about stocks and ETF focused on this innovative area.

Zacks Equity Research

Should Invesco DWA SmallCap Momentum ETF (DWAS) Be on Your Investing Radar?

Style Box ETF report for DWAS

Zacks Equity Research

Should Invesco DWA SmallCap Momentum ETF (DWAS) Be on Your Investing Radar?

Style Box ETF report for DWAS

Sweta Killa

Should Invesco DWA SmallCap Momentum ETF (DWAS) Be on Your Investing Radar?

Style Box ETF report for DWAS

Sweta Killa

Should PowerShares DWA SmallCap Momentum Portfolio (DWAS) Be on Your Investing Radar?

Style Box ETF report for DWAS

Zacks Equity Research

Mirati Therapeutics (MRTX) Soars: Stock Adds 13.6% in Session

Mirati Therapeutics (MRTX) saw a big move last session, as its shares jumped nearly 14% on the day, amid huge volumes.

Zacks Equity Research

Options Traders Expect Huge Moves in Mirati Therapeutics (MRTX) Stock

Mirati Therapeutics (MRTX) needs Investors to pay close attention to the stock based on moves in the options market lately.

Zacks Equity Research

Mirati Therapeutics (MRTX) Rises: Stock Moves 10.9% Higher

Mirati Therapeutics, Inc. (MRTX) moved big last session, as its shares rose almost 11% on the day.

Zacks Equity Research

Mirati Therapeutics (MRTX) Rises: Stock Moves 11.5% Higher

Mirati Therapeutics, Inc. (MRTX) shares rose over 11% in the last trading session.